Literature DB >> 23178461

Breast regression protein-39 (BRP-39) promotes dendritic cell maturation in vitro and enhances Th2 inflammation in murine model of asthma.

Qian Xu1, Shou-jie Chai, Ying-ying Qian, Min Zhang, Kai Wang.   

Abstract

AIM: To determine the roles of breast regression protein-39 (BRP-39) in regulating dendritic cell maturation and in pathology of acute asthma.
METHODS: Mouse bone marrow-derived dendritic cells (BMDCs) were prepared, and infected with adenovirus over-expressing BRP-39. Ovalbumin (OVA)-induced murine model of acute asthma was made in female BALB/c mice by sensitizing and challenging with chicken OVA and Imject Alum. The transfected BMDCs were adoptively transferred into OVA-treated mice via intravenous injection. Airway hyperresponsiveness (AHR), inflammation and pulmonary histopathology were characterized.
RESULTS: The expression of BRP-39 mRNA and protein was significantly increased in lung tissues of OVA-treated mice. The BMDCs infected with adenovirus BRP-39 exhibited greater maturation and higher activity in vitro. Adoptive transfer of the cells into OVA-treated mice significantly augmented OVA-induced AHR and eosinophilic inflammation. Meanwhile, BRP-39 further enhanced the production of OVA-induced Th2 cytokines IL-4, IL-5 and IL-13, but significantly attenuated OVA-induced IFN-γ production in bronchoalveolar lavage fluid.
CONCLUSION: In OVA-induced murine model of acute asthma, BRP-39 is over-expressed in lung tissue and augments Th2 inflammatory response and AHR. BRP-39 promotes dendritic cell maturation in vitro. Therefore, BRP-39 may be a potential therapeutic target of asthma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178461      PMCID: PMC4001840          DOI: 10.1038/aps.2012.154

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Julia Kofler; Adam Starkey; Guoji Wang; Clayton A Wiley
Journal:  Brain Pathol       Date:  2011-12-22       Impact factor: 6.508

2.  Serum YKL-40 levels are correlated with symptom severity in patients with allergic rhinitis.

Authors:  J-W Kwon; T-W Kim; S-H Cho; K-U Min; H-W Park
Journal:  Allergy       Date:  2011-04-11       Impact factor: 13.146

3.  YKL-40 in giant cells and macrophages from patients with giant cell arteritis.

Authors:  J S Johansen; B Baslund; C Garbarsch; M Hansen; M Stoltenberg; I Lorenzen; P A Price
Journal:  Arthritis Rheum       Date:  1999-12

Review 4.  The role of dendritic and epithelial cells as master regulators of allergic airway inflammation.

Authors:  Bart N Lambrecht; Hamida Hammad
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

5.  Regulation of YKL-40 production by human articular chondrocytes.

Authors:  J S Johansen; T Olee; P A Price; S Hashimoto; R L Ochs; M Lotz
Journal:  Arthritis Rheum       Date:  2001-04

6.  The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress.

Authors:  Jin-Ah Park; Jeffrey M Drazen; Daniel J Tschumperlin
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

7.  A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid.

Authors:  J S Johansen; H S Jensen; P A Price
Journal:  Br J Rheumatol       Date:  1993-11

8.  Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.

Authors:  S H Gavett; X Chen; F Finkelman; M Wills-Karp
Journal:  Am J Respir Cell Mol Biol       Date:  1994-06       Impact factor: 6.914

Review 9.  Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.

Authors:  C Trumpfheller; M P Longhi; M Caskey; J Idoyaga; L Bozzacco; T Keler; S J Schlesinger; R M Steinman
Journal:  J Intern Med       Date:  2012-01-04       Impact factor: 8.989

Review 10.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

View more
  5 in total

Review 1.  New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma.

Authors:  Daniel Elieh Ali Komi; Tohid Kazemi; Anton Pieter Bussink
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

2.  Adenovirus vector-mediated YKL-40 shRNA attenuates eosinophil airway inflammation in a murine asthmatic model.

Authors:  Ling Wang; Aihua Bao; Ying Zheng; Aying Ma; Yi Wu; Huanxia Shang; Danruo Fang; Suqin Ben
Journal:  Gene Ther       Date:  2020-10-12       Impact factor: 5.250

3.  Chitinase 3-like-1 protects airway function despite promoting type 2 inflammation during fungal-associated allergic airway inflammation.

Authors:  Joseph J Mackel; Jaleesa M Garth; MaryJane Jones; Diandra A Ellis; Jonathan P Blackburn; Zhihong Yu; Sadis Matalon; Miranda Curtiss; Frances E Lund; Annette T Hastie; Deborah A Meyers; Chad Steele
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-02-03       Impact factor: 6.011

4.  Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis.

Authors:  Do-Hyun Kim; Hong-Jai Park; Sangho Lim; Ja-Hyun Koo; Hong-Gyun Lee; Jin Ouk Choi; Ji Hoon Oh; Sang-Jun Ha; Min-Jong Kang; Chang-Min Lee; Chun Geun Lee; Jack A Elias; Je-Min Choi
Journal:  Nat Commun       Date:  2018-02-05       Impact factor: 14.919

5.  Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD.

Authors:  Jing Wang; Huajie Lv; Zhuang Luo; Shan Mou; Jing Liu; Chang Liu; Shiying Deng; Youfan Jiang; Jiachen Lin; Chengzhou Wu; Xianhong Liu; Jinzhi He; Depeng Jiang
Journal:  Respir Res       Date:  2018-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.